Approvals
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
First-Line Bavencio Bladder Cancer OK Boosts Merck KGaA
Pfizer-partnered Bavencio has struggled to compete with other checkpoint inhibitors like Keytruda, Opdivo, Imfinzi and Tecentriq, but could carve out a lucrative niche in first-line urothelial carcinoma.
ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
Pipeline Watch: Phase III Starts In Hypertension, Atopic Dermatitis
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements
Merck & Co. Pushes Back On Modest Projections For Verquvo
Merck & Co.'s vericiguat, an sGC stimulator, was approved for heart failure but it enters a competitive space with a narrow indication.
Pipeline Watch: Phase III Starts In PAH, NSCLC And Seizure Disorders
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
FDA Approval Opens Up Gastric Cancer To Daiichi Sankyo/AZ’s Enhertu
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.
COVID-19 Could Change Attitudes To Flu, Bolster Xofluza
Roche’s first-in-class one-dose antiviral Xofluza has been approved for marketing in the EU to treat influenza in patients aged 12 years or over, and for post-exposure prophylaxis.
Coronavirus Update: Moderna Vaccine Gets UK Go-Ahead As EU Approval of Oxford/AZ Vaccine Due In Weeks
Moderna’s mRNA COVID-19 vaccine has received an approval from the UK’s MHRA, while AstraZeneca is expected to apply for the EU approval of its COVID-19 vaccine next week.
Pipeline Watch: Phase III Readouts in Dry Eye Disease, Amyloidosis And Crohn's Disease
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.